April 4, 2018 / 8:24 PM / 22 days ago

BRIEF-Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial

April 4 (Reuters) - Conatus Pharmaceuticals Inc:

* CONATUS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2B POLT-HCV SVR CLINICAL TRIAL

* THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT IN HETEROGENEOUS OVERALL TRIAL POPULATION

* BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION

* CONATUS PHARMACEUTICALS INC - ENCORE-NF FOR NASH FIBROSIS TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019

* CONATUS PHARMACEUTICALS INC - ENCORE-LF FOR LIVER FUNCTION WITH TOP-LINE RESULTS EXPECTED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below